Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25668252 | 0.83 | CYP1A2 (0.43) | POLBPDCD1CD274 | |
| SCHEMBL13853646 | 0.81 | POLB (0.42) | POLBVNN1 | |
| SCHEMBL21214337 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2KDM4EPDCD1CD274 | |
| SCHEMBL10101693 | 0.78 | POLB (0.50) | POLBVNN1 | |
| SCHEMBL8418345 | 0.74 | POLB (0.70) | POLBHSD11B1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL10207376 | 0.73 | TSHR (0.41) | — | |
| SCHEMBL24127431 | 0.73 | MAPT (0.37) | HSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL19909687 | 0.73 | CHRNB2 (0.36) | HSD11B1KDM4EVNN1 | |
| SCHEMBL10101683 | 0.72 | POLB (0.48) | POLBKMT2A | |
| SCHEMBL16078890 | 0.70 | GPR183 (0.34) | SMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | POLB 1736/4885HSD11B1 2457/4885SMN1; SMN2 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.